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Abstract
BACKGROUND: The aim of the study was to examine in vitro
and in vivo binding of radiolabelled analogues of P149 peptide
by experimental mammary adenocarcinoma with the intention
of potential application for diagnosis and internal radiotherapy
of tumours.
MATERIAL AND METHODS: The 36-amino acid peptide (P149-QY)
of 90% homology to 447–480 peptide fragment of hAFP was
synthesised and radiolabelled with iodine-125. The biodistribu-
tion of P149-Q[125I]-Y was studied in experimental mammary
tumours. For in vitro experiments, extract from mouse mamma-
ry tumours were prepared and incubated with radioiodinated
P149-QY peptide in the presence of a cross-linking reagent.
RESULTS: The gel electrophoresis analysis (SDS-PAGE)
showed that radioiodinated P149-QY peptide formed a com-
plex with adenocarcinoma proteins of about 30 kDa. The bio-
distribution of P149-Q[125I]-Y studied in experimental mammary
tumours revealed a higher pharmacokinetic rate in comparison
with the whole radioiodinated AFP molecule. A moderate up-
take of P149-Q[125I]-Y in the tumour tissue was observed (3.2%
ID/g at 30-min p.i.v). However, a faster radioactivity clearance
from blood and normal tissues resulted in an increase in the
tumour/muscle (T/M) ratio, i.e. from 2.3 to 3.4 after 30 mins and
24 h p.i.v, respectively.
CONCLUSIONS: The present study shows that radioiodinated
P149-QY peptide reveals some positive features as the AFP
receptor radioligand, however, some additional structural mo-
difications of the initial peptide molecule are necessary for full
retention of the ligand-receptor interaction of its radiolabelled
forms.
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Introduction
It has been postulated that the growth of some tumour cells
occurs, among others, through the interaction of a-fetoprotein
(AFP) with cell surface proteins. In further studies, a specific re-
ceptor for AFP (rAFP) was shown to be present on human breast
cancer cells [1–7]. Expression of rAFP on human unproliferating
cells was very low. The amount of rAFP molecules on lymphoma
cells was about 10 times higher in comparison with normal proli-
ferating T lymphocytes [8]. The AFP binding proteins were detec-
table in both soluble and membrane bound forms, revealing di-
fferent molecular masses [9–11]. Therefore, attempts have been
made to utilize the radiolabelled AFP molecule for in vivo detec-
tion of neoplastic foci [12–14]. It has been observed in vivo that
mouse mammary carcinoma preferentially incorporated radiola-
belled AFP in comparison with the normal tissue [12]. Additional-
ly, a significantly higher accumulation of labelled [131I]-AFP in mouse
mammary adenocarcinoma than in rat mammary adenoma has
also been noticed [14]. Like other radiolabelled proteins and ma-
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cromolecules, [131I]-AFP revealed high retention in blood and slow
pharmacokinetics, that are the main drawbacks of its application
as an in vivo imaging agent.
AFP, like some proteins, may serve as precursor molecules,
which contain multiple modular sequences, or cassette segments,
generated by proteolytic digestion to produce smaller biologically
active peptides. Pro-opiomelanocortin, among others, is a classi-
cal example of such proteins, which after cleavage at various argi-
nine-lysine sites may be a source for biologically active hormones
such as g- a- and b-melanocyte stimulating hormones, b-endor-
phin, b-lipotrophic hormone and ACTH [15]. Epidermal growth
factor-like (EGF) proteins can also be the source of a broad spec-
trum of proteins associated with cell adhesion, neural develop-
ment, blood coagulation, fibrinolysis and others [15–17].
Recently, a 34-amino-acid fragment 447–480 of human AFP
(P149) located on the third domain was derived, and it was shown
that the peptide retained the anti-estrogenic activity [18, 19]. The
peptide was identified as AFP estrogen-binding pocket, which
might bind to the AFP cell surface receptor [18]. It has also been
shown that P149 peptide possesses an anti-breast cancer activi-
ty and growth inhibition activity in non-tumour mouse uterine as-
say [18–23], and it probably plays a crucial role in binding AFP
molecules to rAFP [18].
In the present study, in vitro and in vivo binding of radiola-
belled analogue of P149 peptide by experimental mammary ade-
nocarcinoma was investigated with the intention of its potential
application for diagnosis and internal radiotherapy of tumours.
Material and methods
P149-QY synthesis
The 36-amino acid peptide (named P149-QY; Molecular
weight: 3721 Da) of the following sequence: EEDKLLACGEGAA-
-DIIIGHLCIRHEMTPVNPGVG-QY-COOH was prepared by stan-
dard solid phase techniques on a benzhydrylamine resin, using
Boc-protected amino acids. The peptides were cleaved from the
resin and deprotected by treatment with hydrofluoric acid. The
crude peptides were purified on the Vydac C18 reverse phase HPLC
column. The purity of the peptides was estimated to be over 95%.
The structure was confirmed by FAB mass spectrometry.
Radioiodination of P149-QY peptide
125I-labelled P149-QY peptide was prepared by the Iodo-gen
method. 0.5 mg of P149-QY peptide was dissolved in 20 ml of 0.2 M
aqueous Na2CO3. 50 ml of 0.1M phosphate buffer of pH 6.9 and
10 ml of Na125I (50 MBq) solution were added. Radioiodination re-
action was started by transferring the mixture into a conical vial
coated with 50 mg of 1,3,4,6-tetrachloro-3a-6a-diphenyl glycoluril
(Iodo-gen, Pierce Chemical Co.). The iodination mixture was gen-
tly vortexed for 30min at room temperature. Then 100 ml of 1%
acetic acid was added, and the mixture was transferred to an SPE
C18 column (100 mg, LiChrolut, Merck), previously equilibrated
with 0.1 M phosphate buffer of pH 6.0. The extraction column was
washed with two 0.5 ml portions of phosphate buffer (pH 6.0),
and finally with 0.5 ml of redistilled water. The radiolabelled pep-
tide was extracted from the column by three portions (3 × 0.3 ml)
of 40% ethanol in 0.1 M phosphate buffer of pH 8.0.
Radiochemical analysis
The radiochemical purities of the preparations were determined
by RP-HPLC and paper electrophoresis methods. HPLC condi-
tions were as follow: Luna C18 5 mm 150 × 4.6 column; mobile
phase: (A) 50 mM phosphate buffer pH 10.0, (B) 100% Acetoni-
trile; gradient: 20% B to 100% B in 15min, 100% B for 10 min; flow
rate = 0.5 ml/min; oven temp. 30°C; sample 10 ml, on-line UV
and radiometric detection. Paper radioelectrophoresis was
applied for qualitative and quantitative evaluation of the radio-
chemical purity and stability of the P149-Q[125I]Y samples. The
electrophoretic mobility of the samples’ constituents were determined
on Whatman 1 MM strips (2 cm wide, 38 cm long) in a 17 V/cm
field gradient, using an electrolyte of 0.05 M natrium perchlorate
(NaClO4). The migration of radioactive bands on the strips were
analysed by autoradiographic method using Radio-TLC Scanner
MINI-SCAN (BIOSCAN) and Laura radio-chromatographic
software.
Cross-linking assays of P149-QY
peptide with receptor
For in vitro experiments, extracts from mammary tumours
were prepared and incubated with radioiodinated P149-QY pep-
tide in the presence of cross-linking reagent ethylene glycol-bis
(succinimidyl succinate). The mixture was subjected to sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (12.5%
SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) mem-
branes and analysed by autoradiography. All experiments, in-
cluding tumour extract preparation and cross-linking assays of
P149-Q[125I]Y peptide with receptor, were carried out according
to Mirowski et al [14].
Biodistribution studies
of radiolabelled P149-QY peptide
The in vivo experiments were performed using the tumour
model of transplantable mammary adenocarcinoma in C3H/W
mice, obtained after subcutaneous injection of the cells suspen-
sion derived from animals bearing spontaneously growing mam-
mary tumours (histologically classified as mammary adenocarci-
noma). The tumour-bearing animals were purchased from the
Department of Genetics and Laboratory Animal Breeding Cancer
Centre, Institute of Oncology in Warsaw. The animals with tumour
sizes ca 0.8 cm in diameter were used for biodistribution studies.
Preparations of 125I-labelled P149-QY peptide were adminis-
tered intravenously in doses of 0.5–1.0 MBq in 0.1 ml single injec-
tions. During the experiment, the animals were housed in meta-
bolic cages in which urine was collected. The animals were an-
aesthetised and sacrificed at 30 min, 2 h and 24 h post intrave-
nous injection (p.i.v.), and then selected tissues were taken out.
The radioactivity of the blood pool, urine, and samples of weight-
ed tissues and carcasses was measured using a gamma counter
supplied with an adapter for whole-body measurement. The re-
sults were calculated as a percentage of the dose in organs (%ID)
or a percentage of the dose per gram of tissue (%ID/g).
The animal experiments were approved by The 4th Local Ani-
mal Ethics Committee in Warsaw (authorization number ZB/3/
/2001), and were carried out in accordance with the principles of
good laboratory practice (GLP).
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Results and Discussion
Recently we have shown that the accumulation of radioio-
dine-labelled fetoprotein in mouse mammary adenocarcinoma was
significantly higher than that in rat mammary adenoma [14]. This
phenomenon is probably connected with the observation that
neoplastic cells expressed receptor(s) specific for AFP. Their num-
ber per cell ranged from 2,000–300,000 [5]. This hypothesis was
further confirmed by the method based on chemical cross-lin-
king, where AFP-binding protein with molecular weight of about
30 kDa was detected in the extract prepared from mammary
adenocarcinoma tissue [14].
In the present study, the 36-amino acid peptide of 90% homo-
logy to 447–480 peptide fragment of hAFP (named as P149-QY)
was synthesized and radiolabelled with I-125 radionuclide. The
introduction of the tyrosine amino-acid at the C-terminal end en-
abled preparation of the radioiodinated P149-Q[125I]Y peptide with
a yield of ca 50–75%. Figure 1 shows the exemplary radioelectro-
phoregrams of the radioiodination mixture, and the P149-Q-[125I]Y)
isolated and purified on SPE C18 cartridge. The radiochemical purity
of the preparation was usually in the range 92–97% (mean 95%),
and it was quite stable during storage for a few days in a refrige-
rator. RP HPLC analysis confirmed the identity and radiochemical
purity of the radioiodinated P149-QY peptide (Figure 2).
To answer if the investigated peptide may interact with tumour
cells through AFP receptor (rAFP), we used the method based on
chemical cross-linking between the probable receptor and the
radio-labelled ligand. Like the parent AFP molecule, the peptide
fragment P149-Q[125I]Y formed a complex with mouse mammary
adenocarcinoma extract protein, which revealed a molecular
weight of about 30 kDa (Figure 3). A similar molecular weight of
radiolabelled complex was observed for AFP molecule [14],
suggesting that [125I]-AFP and its fragment (P149-Q-[125I]Y) interact
with the same protein from the mouse mammary adenocarcino-
ma extract. On the basis of our data, we can conclude that the
interaction between AFP molecule and its receptor is possible
through the amino-acid sequence present in the investigated pep-
tide. However, further studies are needed to obtain a final answer
about the length of such sequence, as well as about its binding
protein present in the mammary adenocarcinoma extract.
Biodistribution studies in tumour-bearing mice have shown
a higher pharmacokinetic rate of P149-Q[125I]Y (Table 1) compared
with the radioiodinated [131I]-AFP molecule [14]. More than 40 and
ca 70% of injected dose of P149-Q[125I]Y were excreted with urine
Figure 1. The electrophoregrams, on Whatman paper, of the radioiodination mixture (top), and the P149-Q[125I]-Y peptide isolated by SPE C18 technique
(bottom). X-scale: “0”— cathode, “250”— anode, “100”— point of the sample application.
Figure 2. The HPLC chromatograms of the P149-Q[125I]-Y purified on SPE C18, and native peptide molecule (UV-280 nm).
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2 and 24 h post administration, respectively. Relatively high accu-
mulation in the stomach (18–20%ID/g) was observed, suggesting
some instability of the radioiodinated peptide in vivo. However,
the constant value of radioactivity retained in the stomach, like-
wise the decreasing concentration of activity in the thyroid gland
(Table 1), do not indicate continuous release of the free radioio-
dine. Moderate and decreasing uptakes in the tumour tissue were
observed (from 3.23 to 1.60 %ID/g after 0.5 and 24 h p.i.v., re-
spectively, Table 1). Notwithstanding, due to a faster radioactivity
clearance from normal muscular tissue, and from the blood, the
tumour/muscle (T/M) and the tumour/blood (T/B) ratios increased
with time post administration (Figure 4), suggesting that part of
the applied peptide was strongly retained in the tumour tissue. Such
behaviour of the radioiodinated peptide in vivo may suggest the
specific mechanism of its binding and retention in the tumour cells,
probably due to ligand-receptor interaction, and promises its better
characteristic as a potential in vivo tracer for scintigraphy of tumours
in comparison to the whole radiolabelled AFP glycoprotein.
The two cysteines present in P149 peptide may favour, in so-
lution, the intrapeptide disulfide bond formation [22, 23] that leads
to loss of anti-growth activity of the peptide. MacColl et al [23]
observed also that the presence of some ions may influence the
peptide activity e.g. Zn(II) ion binds to P149 peptide, stabilising its
active form but Co(II) ion acts in reverse, catalysing the loss of
peptide activity. Therefore, some efforts should be made to pre-
vent formation of the inactive form of the peptide in the radiolabe-
lling process, or a new peptide analogue should be synthesised,
e.g. from which the two cysteine residues would be replaced by
two alanines. The 2 Cys = > 2Ala replacement analogue cannot
form a disulfide bond. Recently, it was shown that such a peptide
was active in the inhibition of the growth of prostate and breast
cancer cell lines, as well as against breast cancer in vivo [24, 25].
In conclusion, our study shows that radioiodinated P149-QY
peptide reveals some positive features as the AFP receptor radio-
ligand. However, some additional structural modifications of the
initial peptide molecule may perhaps improve avidity of the pep-
tide with the receptor.
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Table 1. Biodistribution of P149-Q[125I]-Y peptide in tumour-bearing
C3H/W mice (%ID/g mean and SD; n = 6)
Organ/Tissue 0.5 h p.i.v. 2 h p.i.v. 24 h p.i.v.
 Blood (1 ml) 6.86 ± 1.78 4.15 ± 0.37 1.65 ± 0.20
 Thyroid gland 5.43 ± 1.21 6.25 ± 0.29 3.13 ± 0.65
 Lung 1.78 ± 0.01 1.69 ± 0.27 2.04 ± 0.86
 Liver 2.97 ± 0.62 1.68 ± 0.15 0.85 ± 0.11
 Kidney 13.41 ± 1.70 12.73 ± 2.58 6.32 ± 2.49
 Stomach 18.85 ± 3.44 18.60 ± 2.12 20.08 ± 4.12
 Intestines 4.17 ± 0.49 3.62 ± 0.51 2.85 ± 0.19
 Tumour 3.23 ± 0.41 2.83 ± 0.45 1.60 ± 0.35
 Muscle 1.40 ± 0.19 1.20 ± 0.28 0.47 ± 0.02
 Urine [%ID] 26.76 ± 0.98 41.10 ± 4.29 66.98 ± 7.48
Figure 3. Autoradiographic analysis of P149-Q[125I]-Y peptide before (1)
and after (2) incubation with mouse mammary adenocarcinoma proteins
in the presence of cross-linking reagent.
Figure 4. Variations of in vivo concentration of P149-Q[125I]Y in mouse
mammary adenocarcinoma (bars) with time after administration, in rela-
tion to ratios of the tumour/muscle (solid line) and the tumour/blood
(dashed line).
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